File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: A retrospective analysis of efficacy, safety, and survival benefits

TitleThe use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: A retrospective analysis of efficacy, safety, and survival benefits
Authors
Keywordsadvanced hepatocellular carcinoma
adverse events
Child-Pugh A
Child-Pugh B
sorafenib
Issue Date2012
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
Citation
Cancer, 2012, v. 118 n. 21, p. 5293-5301 How to Cite?
AbstractBackground: This study explored the efficacy, tolerability, and survival benefits of using sorafenib in patients with Child-Pugh class B (CPB) cirrhosis. Methods: Patients with advanced hepatocellular carcinoma who were treated with sorafenib at Queen Mary Hospital, Hong Kong, China, were analyzed retrospectively. Treatment outcomes were analyzed according to their respective Child-Pugh status. Patients with CPB disease were further divided into CPB7 (those with a score of 7) and CPB8-9 (a score of 8 or 9) subgroups. Results: The baseline demographic parameters were comparable between 108 patients with Child-Pugh class A (CPA) disease and 64 CPB patients. Both clinical benefit rate (21.3% vs 32.4% vs 14.8%; P =.23) and progression-free survival (median: 3.2 months vs 3.2 months vs 2.3 months; P =.26) were similar among CPA, CPB7, and CPB8-9 groups, respectively. The overall survival was different among these groups (P =.002) and showed a trend toward worse outcome in CPB patients: the median was 6.1, 5.4, and 2.7 months among CPA, CPB7, and CPB8-9 patients, respectively. The commonest grade 3/4 adverse events were hand-foot syndrome (13.5%), diarrhea (9.9%), and rash (7.0%). Grade 3/4 leukopenia, thrombocytopenia, and anemia occurred in 2.9%, 5.3%, and 8.8% of the patients, respectively. Overall, the 3 groups of patients experienced similar incidence of most of these adverse events. Nonetheless, CPB patients experienced more anemia (P =.01), gastrointestinal bleeding (P =.02), and hepatic encephalopathy (P =.02). Conclusions: CPA and CPB patients tolerated sorafenib similarly and derived similar clinical and progression-free survival benefit. Among CPB patients, most benefits were observed in patients with a score of 7. Nevertheless, CPB patients were more susceptible to developing cirrhotic complications, and thus more vigilant surveillance is needed. Cancer 2012. © 2012 American Cancer Society. with Child-Pugh class A and B cirrhosis tolerated sorafenib similarly and derived similar survival benefit. Among patients with Child-Pugh class B disease, most benefits were observed in patients with a score of 7. © 2012 American Cancer Society.
Persistent Identifierhttp://hdl.handle.net/10722/159622
ISSN
2015 Impact Factor: 5.649
2015 SCImago Journal Rankings: 3.188
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChiu, Jen_HK
dc.contributor.authorTang, YFen_HK
dc.contributor.authorYao, TJen_HK
dc.contributor.authorWong, Aen_HK
dc.contributor.authorWong, Hen_HK
dc.contributor.authorLeung, Ren_HK
dc.contributor.authorChan, Pen_HK
dc.contributor.authorCheung, TTen_HK
dc.contributor.authorChan, ACen_HK
dc.contributor.authorPang, Ren_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorPoon, Ren_HK
dc.contributor.authorYau, Ten_HK
dc.date.accessioned2012-08-16T05:53:28Z-
dc.date.available2012-08-16T05:53:28Z-
dc.date.issued2012en_HK
dc.identifier.citationCancer, 2012, v. 118 n. 21, p. 5293-5301en_HK
dc.identifier.issn0008-543Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/159622-
dc.description.abstractBackground: This study explored the efficacy, tolerability, and survival benefits of using sorafenib in patients with Child-Pugh class B (CPB) cirrhosis. Methods: Patients with advanced hepatocellular carcinoma who were treated with sorafenib at Queen Mary Hospital, Hong Kong, China, were analyzed retrospectively. Treatment outcomes were analyzed according to their respective Child-Pugh status. Patients with CPB disease were further divided into CPB7 (those with a score of 7) and CPB8-9 (a score of 8 or 9) subgroups. Results: The baseline demographic parameters were comparable between 108 patients with Child-Pugh class A (CPA) disease and 64 CPB patients. Both clinical benefit rate (21.3% vs 32.4% vs 14.8%; P =.23) and progression-free survival (median: 3.2 months vs 3.2 months vs 2.3 months; P =.26) were similar among CPA, CPB7, and CPB8-9 groups, respectively. The overall survival was different among these groups (P =.002) and showed a trend toward worse outcome in CPB patients: the median was 6.1, 5.4, and 2.7 months among CPA, CPB7, and CPB8-9 patients, respectively. The commonest grade 3/4 adverse events were hand-foot syndrome (13.5%), diarrhea (9.9%), and rash (7.0%). Grade 3/4 leukopenia, thrombocytopenia, and anemia occurred in 2.9%, 5.3%, and 8.8% of the patients, respectively. Overall, the 3 groups of patients experienced similar incidence of most of these adverse events. Nonetheless, CPB patients experienced more anemia (P =.01), gastrointestinal bleeding (P =.02), and hepatic encephalopathy (P =.02). Conclusions: CPA and CPB patients tolerated sorafenib similarly and derived similar clinical and progression-free survival benefit. Among CPB patients, most benefits were observed in patients with a score of 7. Nevertheless, CPB patients were more susceptible to developing cirrhotic complications, and thus more vigilant surveillance is needed. Cancer 2012. © 2012 American Cancer Society. with Child-Pugh class A and B cirrhosis tolerated sorafenib similarly and derived similar survival benefit. Among patients with Child-Pugh class B disease, most benefits were observed in patients with a score of 7. © 2012 American Cancer Society.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741en_HK
dc.relation.ispartofCanceren_HK
dc.subjectadvanced hepatocellular carcinomaen_HK
dc.subjectadverse eventsen_HK
dc.subjectChild-Pugh Aen_HK
dc.subjectChild-Pugh Ben_HK
dc.subjectsorafeniben_HK
dc.titleThe use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: A retrospective analysis of efficacy, safety, and survival benefitsen_HK
dc.typeArticleen_HK
dc.identifier.emailYao, TJ: tjyao@hkucc.hku.hken_HK
dc.identifier.emailChan, AC: acchan@hku.hken_HK
dc.identifier.emailPang, R: robertap@hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailPoon, R: poontp@hku.hken_HK
dc.identifier.emailYau, T: tyaucc@hku.hken_HK
dc.identifier.authorityYao, TJ=rp00284en_HK
dc.identifier.authorityChan, AC=rp00310en_HK
dc.identifier.authorityPang, R=rp00274en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.authorityPoon, R=rp00446en_HK
dc.identifier.authorityYau, T=rp01466en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/cncr.27543en_HK
dc.identifier.pmid22517493-
dc.identifier.scopuseid_2-s2.0-84867871965en_HK
dc.identifier.hkuros202664en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84867871965&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume118en_HK
dc.identifier.issue21en_HK
dc.identifier.spage5293en_HK
dc.identifier.epage5301en_HK
dc.identifier.isiWOS:000310083000014-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridChiu, J=36887309300en_HK
dc.identifier.scopusauthoridTang, YF=54879579600en_HK
dc.identifier.scopusauthoridYao, TJ=7401886444en_HK
dc.identifier.scopusauthoridWong, A=55189213800en_HK
dc.identifier.scopusauthoridWong, H=23089414000en_HK
dc.identifier.scopusauthoridLeung, R=52364352500en_HK
dc.identifier.scopusauthoridChan, P=7403497715en_HK
dc.identifier.scopusauthoridCheung, TT=7103334165en_HK
dc.identifier.scopusauthoridChan, AC=15828849100en_HK
dc.identifier.scopusauthoridPang, R=7004376659en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridPoon, R=7103097223en_HK
dc.identifier.scopusauthoridYau, T=23391533100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats